Table 1.
Baseline characteristics of all 87 treated patients and subgroups.
| Characteristic | ssCART‐19 (n = 47) | cCART‐19 (n = 40) | p Value |
|---|---|---|---|
| Male, No. (%) | 24 (51.06) | 25 (62.5) | 0.579 |
| Median age (range), years | 33 (9–64) | 24 (2–68) | 0.079 |
| Median lines of therapy (range) | 3 (2–8) | 4 (2–9) | 0.453 |
| Allogeneic SCT, No. (%) | 13 (27.66) | 6 (15) | 0.787 |
| Bone marrow blasts, % | |||
| ≥50% | 6 (12.77) | 7 (17.5) | 0.820 |
| ≥5% and <50% | 14 (29.79) | 13 (32.5) | |
| ≥0.01% and <5% | 13 (27.66) | 11 (27.5) | |
| <0.01% | 14 (29.79) | 9 (22.5) | |
| Bone marrow blasts (range) | 4.0 (0.01–86.0) | 4.0 (0.02–98.0) | 0.340 |
| High‐risk cytogenetic factors, No. (%) | |||
| BCR/ABL (Ph+) | 12 (25.53) | 9 (22.5) | 0.164 |
| TP53 | 1 (2.13） | 3 (7.5） | 0.910 |
Abbreviations: Ph+, Philadelphia chromosome‐positive; SCT, stem cell transplantation; TP53, TP53 gene mutation.